4 FDA drug decisions on the horizon

03/18/2013 | Investor's Business Daily

The FDA is poised to decide on Biogen Idec's multiple sclerosis drug BG-12 by March 28, while United Therapeutics is set to receive a verdict by March 31 for the lung drug Remodulin. Johnson & Johnson's diabetes drug Invokana and Map Pharmaceuticals' migraine drug Levadex are also set to receive federal decisions by March 31 and April 15, respectively.

View Full Article in:

Investor's Business Daily

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President, Science and Regulatory Affairs
American Beverage Association
Washington, DC
Senior Manager of Medical Management
Network Health
Medford, MA
MEDICAL SCIENCE LIAISON - 14000002RO
Abbott
Columbus, OH
Manager, Medical Management
Network Health
Medford, MA
Executive Medical Director
Aspirus Network Inc
Wausau, WI